Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Truist Financial Corp

Truist Financial Corp decreased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 6.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,788 shares of the biopharmaceutical company’s stock after selling 1,235 shares during the period. Truist Financial Corp’s holdings in Amicus Therapeutics were worth $168,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in FOLD. Wellington Management Group LLP grew its holdings in Amicus Therapeutics by 13.5% during the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after purchasing an additional 2,856,101 shares in the last quarter. Geode Capital Management LLC boosted its stake in Amicus Therapeutics by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock valued at $70,499,000 after acquiring an additional 80,926 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Amicus Therapeutics by 4.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company’s stock valued at $33,749,000 after acquiring an additional 139,491 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Amicus Therapeutics by 10.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,667,271 shares of the biopharmaceutical company’s stock worth $28,486,000 after buying an additional 242,672 shares during the last quarter. Finally, Point72 Asset Management L.P. bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth about $13,530,000.

Amicus Therapeutics Stock Performance

FOLD stock opened at $9.02 on Friday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. The stock has a market cap of $2.77 billion, a P/E ratio of -50.11, a P/E/G ratio of 1.51 and a beta of 0.61. The firm has a 50 day simple moving average of $9.46 and a 200 day simple moving average of $10.29. Amicus Therapeutics, Inc. has a 52 week low of $8.78 and a 52 week high of $12.76.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Guggenheim raised their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. raised their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics has an average rating of “Moderate Buy” and an average target price of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.